References
- Kirkitadze M D, Bitan G, Teplow D B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res. 2002; 69: 561–511
- Selkoe D J, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545–84
- Schenk D. Amyloid-β-immunotherapy for Alzheimer's disease: the end of the beginning. Nature Reviews Neuroscience 2002; 3: 824–828
- Kayed R, Head E, Thompson J L, McIntire T M, Milton S C, Cotman C W, Glabe C G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486–489
- Hammarstrom P, Wiseman R L, Powers E T, Kelly J W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299: 713–116
- Pepys M B, Herbert J, Hutchinson W L, Tennent G A, Lachmann H J, Gallimore J R, Lovat L B, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross R D, Kemp J A, Yamamura K, Suzuki M, Taylor G W, Murray S., Thompson D, Purvis A, Kolstoe S, Wood S P, Hawkins P N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254–259